CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery to Improve Treatment of Melanoma Brain Metastases

ClinicalTrials.gov ID: NCT05669352

Public ClinicalTrials.gov record NCT05669352. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 20, 2026, 1:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

MC250710 A Phase 1/2 Study of Oral IRAK-4 Inhibitor CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery in Patients With Melanoma Brain Metastases

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This phase I/II trial tests how well the combination of CA-4948 with pembrolizumab works to reduce the need for intracranial intervention, such as surgery, additional radiosurgery, laser therapy, or whole brain radiotherapy following stereotactic radiosurgery to improve treating patients with melanoma that has spread from where it first started (primary site) to the brain (metastatic). CA-4948 may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. A monoclonal antibody, such as pembrolizumab, is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Stereotactic radiosurgery is a type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. Giving CA-4948 with pembrolizumab following stereotactic radiosurgery may reduce the need for intracranial interventions and be effective for treating patients with melanoma that metastasized to the brain.

Study identification

NCT ID: NCT05669352
Recruitment status: Suspended
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Mayo Clinic; Other
Enrollment: 23 participants

Conditions and interventions

Conditions

Interventions

Drug · Radiation · Procedure + 1 more

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 30, 2026 (Estimated)
Primary completion: Nov 2028 (Estimated)
Completion: Nov 2028 (Estimated)
Last update posted: Oct 20, 2026

2026 – 2028

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Mayo Clinic in Florida	Jacksonville	Florida	32224-9980	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05669352, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 20, 2026 · Synced Oct 20, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT05669352 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →